Pompe Disease and the CRIM Question: Start Enzyme Replacement Today, or Wait for the Result That Changes Everything
A newborn screens positive for infantile Pompe disease with early signs of cardiac involvement. Starting enzyme replacement immediately protects a heart that can't wait — but starting it before his CRIM status is known could doom the treatment entirely if he turns out CRIM-negative.
Baby N. is twelve days old, the first child of parents who describe the last two weeks as the hardest of their lives — an uncomplicated delivery followed almost immediately by a phone call about an abnormal newborn screen, then a whirlwind of confirmatory testing that has landed them in a cardiac ICU consult room being told their son has infantile-onset Pompe disease. Biallelic pathogenic GAA variants are confirmed. He looks, to his parents, mostly fine: feeding adequately, gaining weight, no respiratory distress, mild generalized hypotonia but no overt weakness.
The echocardiogram obtained on day 10, ordered because of the screen rather than because anyone noticed anything, is where that impression breaks down. His left ventricular mass index is 94 g/m² against a normal infant ceiling near 65 — a z-score of roughly +4 at twelve days of life, in a child with no murmur and no symptom. His CK is elevated above the newborn range. Neither number is remarkable for infantile Pompe disease; both are remarkable for a baby this age who appears well, and together they mean the cardiac remodeling that defines the fastest-moving feature of this illness has already started and is being measured, not predicted.
Enzyme replacement restores the acid alpha-glucosidase his GAA mutations leave nonfunctional, and the early-treatment evidence is unusually good for a rare disease: the Duke cohort work from Kishnani's group, most clearly Desai and colleagues in 2021, stratified CRIM-negative infants by age at initiation and found outcomes improving the earlier treatment began, with the best results in those started within four weeks of birth. That figure cuts in an unexpected direction here. His CRIM result is due in five to seven days, which would put initiation around day 17 to 19 — still inside the four-week window that cohort identified as the favorable one. On the cohort data alone, waiting does not obviously cost him the early-treatment advantage.
What waiting might cost him is specific to his heart rather than to the calendar, and it is the reason CRIM status matters at all. Infants who make no native GAA protein reliably mount high-titer neutralizing antibodies against the infused enzyme unless immune tolerance induction begins with or before the first dose; started afterward, once titers have risen, it is a materially harder and less reliable rescue. So the team is weighing a ventricle already remodeling at four standard deviations above normal against a five-to-seven-day answer that determines whether the first infusion should be given alone or under cover.
In the cardiac ICU consult room, day twelve of life
I'd start enzyme replacement today. His left ventricular mass index is 94 against a normal ceiling near 65 — four standard deviations above the mean, at twelve days, in a baby with no murmur — and infantile Pompe's cardiac involvement is the single fastest-moving feature of this disease — untreated, it can progress to severe outflow obstruction and heart failure within months, sometimes faster than that. The evidence for early ERT is about as strong as it gets in a rare disease: in Desai and Kishnani's 2021 cohort, CRIM-negative infants stratified by age at treatment initiation did progressively better the earlier they started, with the best outcomes in those treated inside the first four weeks. He looks well today. His echocardiogram says his heart doesn't have five to seven days to spare waiting on a lab result.
I recognize I'm arguing from the organ I'm watching most closely, and I want to be upfront about that — but early cardiac decompensation in this disease can move fast enough that 'he looks fine right now' isn't reassuring the way it would be in almost any other newborn consult.
You're right that his heart is the clock that matters most here, and I'm not proposing we simply wait out the full CRIM turnaround with no counter-plan. But starting ERT blind to CRIM status carries a real risk that isn't hypothetical: CRIM-negative infants, who make no native GAA-like protein at all, reliably mount high-titer neutralizing antibodies against the infused enzyme unless immune tolerance induction starts concurrently with the first dose. Add ITI later, after those antibodies have already formed, and it's a materially harder rescue — some infants never regain a working level of ERT efficacy once that happens. If he's CRIM-negative and we start ERT alone today, we could be spending his most time-critical week on a treatment that his own immune system is about to neutralize.
'Start now, worry about antibodies later if they show up' undersells how much the timing of ITI itself matters — this isn't a rescue you can cleanly apply after the fact with the same odds of success. The moment to prevent the antibody response is the first infusion, not the one after we notice titers rising.
I don't think this has to be 'wait for CRIM' versus 'start ERT alone and hope.' Some centers start ERT and a short prophylactic immune tolerance regimen — typically rituximab and methotrexate — at the same time, without waiting for the CRIM result, precisely because of the timing problem the geneticist just described: ITI works best started with the first dose, and a cardiac-urgent infant like this one may not have days to spare waiting on a lab. That captures the cardiologist's timeline while hedging against a CRIM-negative result we don't yet know.
I want to be direct that this isn't a free hedge, and I don't want it presented to his parents as one. Rituximab and methotrexate are real immunosuppression in a twelve-day-old with an already-compromised heart, and if his CRIM result comes back positive in five days, we will have exposed him to that risk for a benefit he turned out not to need. That's a real cost, not a rounding error, and it should be named as one before his parents consent to it.
Agreed, after his parents were walked through all three positions directly: start alglucosidase alfa today, alongside empiric prophylactic rituximab and methotrexate, without waiting for the CRIM result — capturing the cardiac urgency the cardiologist raised while hedging the antibody risk the geneticist described. His parents were told explicitly, in the immunologist's own words, that this means real immunosuppression risk for a benefit that may turn out to be unnecessary if his CRIM result comes back positive.
prophylactic ITI will be tapered per protocol once antibody titers are confirmed low and stable, since the immunosuppression will no longer have a role to play.
ITI continues per the full protocol, and the team will already be ahead of the antibody-formation window that makes CRIM-negative Pompe disease so difficult to rescue once ERT has been running alone.